Ocugen, Inc. Logo

Ocugen, Inc.

Develops gene/cell therapies and vaccines, specializing in blindness and public health.

OCGN | NDAQ

Overview

Corporate Details

ISIN(s):
US43358V1098 (+1 more)
LEI:
Country:
United States of America
Address:
11 GREAT VALLEY PARKWAY, 19355 MALVERN
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company is a pioneer in developing treatments for blindness diseases, leveraging its breakthrough modifier gene therapy platform to address significant unmet medical needs in inherited retinal diseases. Ocugen's development pipeline also extends to vaccines and other biologics aimed at improving public health. The company operates with a patient-centric mission to deliver innovative therapeutic solutions for conditions with limited or no available treatment options.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ocugen, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ocugen, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ocugen, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SYNAIRGEN PLC Logo
Developing inhaled interferon beta treatments for severe viral lung infections in hospitalized patients.
United Kingdom SNG
Synerga Fund Spolka Akcyjna Logo
Commercializes medical therapies globally using industrial property and copyrights for clinical use.
Poland SNG
Synergie SE Logo
Offers global HR services, including temporary/permanent recruitment and workforce solutions.
France SDG
SyntekaBio,Inc. Logo
AI drug discovery platform accelerating R&D with supercomputing, SaaS, and pre-made candidates.
South Korea 226330
Targetspot S.A. Logo
AdTech firm for digital audio monetization, connecting brands to publishers' audiences.
Belgium ALTGS
TechnoPro Holdings, Inc. Logo
Technology staffing and services group providing engineers and solutions for R&D and development.
Japan 6028
TechTarget, Inc. Logo
Provides purchase intent-driven marketing and sales services for B2B tech vendors.
United States of America TTGT
Tenaya Therapeutics, Inc. Logo
Developing gene therapy, cellular regeneration & precision medicine for heart disease.
United States of America TNYA
Terns Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing small-molecule drugs for oncology & metabolic diseases.
United States of America TERN
A holding company active in property rentals and marine seismic & defense R&D.
Virgin Islands (British) THAL

Talk to a Data Expert

Have a question? We'll get back to you promptly.